Patent Highlights: NLRP3 and NaV1.8 Inhibitors, SMARCA2 Degraders, and More from December 2023

We know keeping up with the latest developments in drug discovery can be a challenge, so we’ve simplified the process for you. We’ve reviewed thousands of newly published patent documents to bring you a curated list of over 200 key patents released in August 2024. Each entry comes with detailed commentary to help you navigate the content quickly and efficiently.

This article highlights a patent application from Constellation Pharmaceuticals that discloses the biological activity of compounds that act as TREX1 inhibitors, providing a summary of key data for selected molecules disclosed in the patent application.

In this article, you'll find a curated selection of >70 molecules from August that piqued our interest, highlights of some of our favorites, and explanations of why they're worth watching.

Drug Hunter has sifted through news articles, press releases, financial disclosures, SEC filings and more to bring you a roundup of 2023's biggest mergers and acquisitions (M&A) in the drug discovery world. In this 4-part series we will give you an open-access overview of the M&A landscape, and then for Drug Hunter members in the coming weeks, we will be providing in-depth coverage and analysis of the small molecule-focused (parts 2 & 3) and biologics-based deals (part 4). This premium content includes background on the targets, chemical/biological matter and clinical data driving these deals.

In this article, we present a curated selection of over 60 molecules from September that caught our attention, along with highlights of our top picks and insights into why they stand out.